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Patients with end-stage renal disease (ESRD) have elevated circulating calcium (Ca) and
phosphate (Pi), and exhibit accelerated progression of calcific aortic valve disease (CAVD). We
hypothesized that matrix vesicles (MVs) initiate the calcification process in CAVD. Ca induced
rat valve interstitial cells (VICs) calcification at 4.5mM (16.4-fold; p < 0.05) whereas Pi
treatment alone had no effect. Ca (2.7 mM) and Pi (2.5 mM) synergistically induced calcium
deposition (10.8-fold; p < 0.001) in VICs. Ca treatment increased the mRNA of the osteogenic
markersMsx2, Runx2, and Alpl (p < 0.01). MVs were harvested by ultracentrifugation from VICs
cultured with control or calcification media (containing 2.7 mM Ca and 2.5 mM Pi) for 16 hr.
Proteomics analysis revealed the marked enrichment of exosomal proteins, including CD9,
CD63, LAMP-1, and LAMP-2 and a concomitant up-regulation of theAnnexin family of calcium-
binding proteins. Of particular note Annexin VI was shown to be enriched in calcifying VIC-
derived MVs (51.9-fold; p < 0.05). Through bioinformatic analysis using Ingenuity Pathway
Analysis (IPA), the up-regulation of canonical signaling pathways relevant to cardiovascular
function were identified in calcifying VIC-derived MVs, including aldosterone, Rho kinase, and
metal binding. Further studies using human calcified valve tissue revealed the co-localization of
Annexin VI with areas of MVs in the extracellular matrix by transmission electron microscopy
(TEM). Together these findings highlight a critical role for VIC-derived MVs in CAVD.
Furthermore, we identify calcium as a key driver of aortic valve calcification, whichmay directly
underpin the increased susceptibility of ESRD patients to accelerated development of CAVD.
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1 | INTRODUCTION
Calcific aortic valve disease (CAVD), and subsequent aortic valve
stenosis is the most common heart valve disease in the Western
world (Newby, Cowell, & Boon, 2006; Nkomo et al., 2006). CAVD is
currently considered an actively regulated and progressive disease,
characterized by a cascade of cellular changes that initially cause
fibrotic thickening, followed by an extensive calcification of the
aortic valve leaflets. This in turn leads to significant aortic valve
stenosis and eventual left ventricular outflow obstruction (Freeman
& Otto, 2005), for which surgical replacement remains the only
viable treatment option.
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Patients with end-stage renal disease (ESRD) have high circulating
calcium (Ca) phosphate (Pi) levels, and develop extensive vascular
calcification which directly contributes to cardiovascular morbidity
(Jablonski & Chonchol, 2013; Moe & Chen, 2004; Zhu, Mackenzie,
Farquharson, &Macrae, 2012). ESRDpatients are highly susceptible to
accelerated progression of CAVD (Perkovic et al., 2003; Rattazzi et al.,
2013; Umana, Ahmed, & Alpert, 2003), however, this association has
received little attention to date.
The pathophysiology of CAVD is complex, but shares similar
mechanisms to physiological bone mineralization (Mohler et al., 2001).
Valve interstitial cells (VICs), the most abundant cell type in the aortic
heart valve, play a key role in CAVD progression. Numerous studies
have demonstrated the ability of VICs to undergo osteogenic trans-
differentiation and calcification (Monzack & Masters, 2011; Osman,
Yacoub, Latif, Amrani, & Chester, 2006). While the mechanisms
underpinning this process have yet to be fully elucidated, it is highly
plausible that parallels with chondrocyte and vascular calcification
exist, whereby matrix vesicles (MVs) initiate the calcification process
through interactions with collagen within the extracellular matrix
(ECM) (Chen,ONeill, Chen, &Moe, 2008; Kapustin & Shanahan, 2012;
New et al., 2013).
MVs are membrane-bound particles of cellular origin, ranging
from 100 to 200 nm in diameter, and act as a nidus for hydroxyapatite
nucleation (Cui, Houston, Farquharson, & MacRae, 2016). Vascular
smooth muscle cell (VSMC)-derived MVs have been associated
with arterial calcification (Kapustin et al., 2011), with recent studies
elucidating their composition, interrogating their function, and
identifying these MVs as exosomes (Kapustin et al., 2011, 2015).
However, the role of MVs in CAVD has yet to be fully determined.
This study aimed to characterize the role of MVs during aortic
valve calcification. We have therefore, undertaken analysis of clinical
CAVD tissues in conjunction with in vitro calcification studies in rat-
derived VICs to address the hypothesis that Ca and Pi induce aortic
valve calcification through a MV-mediated mechanism.
These findings yield novel insights into the mechanisms of CAVD
and highlight a critical role for the involvement of VIC-derived MVs.
Furthermore, we identify Ca as a key driver of aortic valve calcification,
which may directly underpin the increased susceptibility of ESRD
patients to accelerated development of CAVD.
2 | METHODS
2.1 | Human tissues
Human aortic valve samples were obtained with appropriate ethical
approval from patients undergoing valve replacement surgery (Ethics
Number: 13/ES/0126). Research ethics committee approval (National
Health Service West of Scotland Research Ethics Committee: 12/WS/
0227) and the written and informed consent of all participants were
obtained. The uncalcified control tricuspid valve tissue was from a
79-year old female with aortic incompetence and generalized aortic
dilatationwithascendingaorta involvement.Therewasminor tomoderate
left ventricular impairment. Calcified tricuspid valve tissue was from a
67-year old female with severe aortic stenosis detected by echocardiog-
raphy. Angiography revealed severe distal left mainstem stenosis with
further moderate disease in the left anterior descending artery and
circumflex and a severe lesion within the diagonal artery. Additionally,
therewasa90%stenosis in themid right coronaryartery.Theaortic valves
were removed at the time of aortic valve replacement with care taken to
preserve the integrity of the valve architecture. Human tissuewas used in
this study in conformation with the declaration of Helsinki.
2.2 | Primary rat VIC isolation
All animal experiments were approved by The Roslin Institutes Animal
Users Committee and the animals weremaintained in accordance with
Home Office guidelines for the care and use of laboratory animals.
Rats used were euthanized by cervical dislocation. Primary aortic VICs
were isolated from aortic valve leaflets, dissected from the hearts of
5 weeks old male Sprague Dawley rats (Charles River Laboratories,
Harlow, UK). Leaflets were initially digested in 425U/ml collagenase
type II (Worthington, Lakewood, NJ) for 10min and washed in Hanks
balanced salt five solution (HBSS; Life Technologies, Paisley, UK) to
remove valve endothelial cells. The leaflets were subsequently
digested with 425 U/ml collagenase type II for a further 2 hr. The
cells subsequently obtained were re-suspended in growth media
consisting of Dulbeccos Modified Eagle Media (DMEM)-Formula 12
(Life Technologies) supplemented with 10% foetal bovine serum (FBS;
Life Technologies) and 1% gentamicin (Life Technologies) and cultured
at 37 °C, in the presence of 5% CO2. Before experimentation, isolated
VICs were expanded in growth media for 24 passages, and cells used
for experiments were between passage 46.
2.3 | Rat VIC line
The RVIC Sv40T (rat VIC-derived cell line) was generated by
transducing primary rat VICs with recombinant lentivirus expressing
Simian virus (SV) 40 large T antigen. Cell immortalization is achieved
by silencing the expression of the tumor suppressors such as p53
and retinoblastoma protein (Rb), through a siRNA expressed by the
lentivirus (Capital Biosciences, Gaithersburg, MD).
2.4 | Induction of calcification
PrimaryVICswere seeded ingrowthmedia at adensityof1.67 × 104/cm2
in multi-well plates. Calcification was induced as previously described in
VSMCs (Reynolds et al., 2004). In brief, cells were grown to confluence
(Day 0) before treatment with control (1.05mM Ca/0.95mM Pi) or test
media; high calcium (Ca media; 2.7, 3.6, 4.5, or 5.4mM Ca), high
phosphate (Pi media; 2, 2.5, 3, 4, or 5.0mM Pi), or both (CaPi media;
1.52.7mM Ca/1.52.5mM Pi). The standard CaPi media used was
2.7mM Ca and 2.5mM Pi. VICs were incubated for up to 5 days in 5%
CO2 at 37 °C, and the medium was changed every 2nd/3rd day.
2.5 | Determination of calcification
Calcium deposition was quantified based on a method previously
described (Zhu et al., 2015; Zhu, Mackenzie, Millan, Farquharson,
& Macrae, 2014). Briefly, cells were rinsed twice with phosphate
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buffered saline (PBS) and decalcified with 0.6 M HCl at room
temperature for 2 hr. Free calcium was determined colorimetri-
cally by a stable interaction with phenolsulphonethalein, using a
commercially available kit (Randox Laboratories Ltd., County
Antrim, UK), and corrected for total protein concentration (Bio-
Rad Laboratories Ltd, Hemel Hempstead, UK).
2.6 | MV isolation
MVs were obtained by differential centrifugation using a modified MV
isolation protocol (Reynolds et al., 2004). Primary VICs or RVIC Sv40T
cellswere cultured in control (serum free growthmedia) or in serum free
standard CaPi media, for 16 hr at 37 °C. The media was subsequently
aspirated and centrifuged at 3000 g for 20min to pellet cell debris. The
supernatant was then transferred to Beckman Coulter Ultra Clear™
ultracentrifuge tubes (VWR International Ltd, Lutterworth, UK) and
centrifugedat 270,000 g for 1 hr at 4°C, using aBeckmanOptimaXL-90
ultracentrifuge (Beckman Coulter, Buckinghamshire, UK). The superna-
tant was discarded and the pellets were re-suspended in PBS. The
concentration of pelletedMVswasmeasured usingDC assay (Bio-Rad).
2.7 | Fluorescent immunocytochemical staining
Cell monolayers on glass coverslips, were fixed with 4% paraformalde-
hyde (PFA) and washed with PBS. Fixed cells were permeabilized with
0.3%TritonX100 (Sigma,Dorset,UK)and incubatedwithanti-α-smooth
muscle actin (α-SMA; 1:100; Sigma), anti-vimentin (1:900) or anti-CD31
(1:900) (Abcam, Cambridge, UK) overnight at 4°C. After washing, cells
were incubated with Alexa Fluor® 488 donkey-anti-rabbit antibody or
Alexa Fluor® 594 goat-anti-mouse antibody (1:250; ThermoFisher
Scientific, Northumberland, UK) for 1 hr in the dark. Glass coverslips
were mounted onto slides with Prolong Gold Anti-Fade Reagent
contained DAPI (Life Technologies). Fluorescence signal was detected
under a Leica DMRB fluorescence microscope (Leica Biosystems, Milton
Keynes, UK). Control sections were incubated with non-immune mouse
or/and rabbit IgG (Sigma) (2μg IgG/ml) in place of the primary antibody.
2.8 | Transmission electron microscopy
Human valve tissue samples were cut into 12mm3 pieces and fixed
in 2.5% glutaraldehyde in 0.1M sodium cacodylate buffer (pH 7.4).
Samples were then processed with an automated routine tissue
processor, LeicaEMTP (LeicaBiosystems) througha series of dehydration
steps and penetration using TAAB 812 Epoxy resin (TAAB, Aldermaston,
UK). The samples were then polymerized in TAAB embedding capsules
(TAAB), sectioned at 0.5μm, stained with toluidine blue, and scanned
using a Zeiss Axioscan Z1 slide scanner (Carl Zeiss, Jena, Germany).
Ultrathin sections (thickness 90 nm)were prepared on a Leica UC6 (Leica
Biosystems) and contrasted with 5% uranyl acetate for 15min, and lead
citrate for 5min, on a Leica AC20 (Leica Biosystems). For immunogold
labeling, the sampleswere initially fixed in 0.5%glutaradehyde in4%PFA.
Following the same routine electron microscopy routine (using LRWhite
Resin; TAAB), after ultrathin sectioning to 60 nm thick, the sections were
collected on formvar-carbon coated nickel grids, then heated in citrate
buffer (pH 6) before letting the samples cool down. The slides were
blocked with 5% bovine serum albumin (BSA; Sigma) for 1 hr before
incubating with anti-annexin VI antibody (1:1000; Santa Cruz Biotech-
nology, Dallas, TX), at 4 °C, overnight. On the following day, they were
incubated with rabbit anti-goat Gold antibody (1:300, Sigma) at room
temperature, for 2 hr. Finally, they were contrasted with 5% uranyl
acetate for 15min, and lead citrate for 5min as mentioned previously.
Samples were viewed on a JEOL 1400/JEM plus (JEOL,Welwyn Garden
City, UK) with AMT UltraVUE camera (AMT, Bury St. Edmunds, UK) and
Gatan OneView camera (Gatan, Oxon, UK).
2.9 | Histology and immunohistochemistry
Tissues were fixed in 10% neutral buffered formalin (NBF) for 24 hr
before being dehydrated, embedded in paraffin wax, and sectioned
(4 μm) using standard procedures as previously described (Zhu et al.,
2016). Sectionswere de-waxed in xylene and stainedwithVonKossa or
Alizarin red (Sigma) to visualize Ca deposition, and haematoxylin and
eosin (H&E) to assess cell architecture. Immunohistochemistry was
performed using the Vectastain ABC Kit (Goat IgG) (Vector Labs,
Peterborough, UK) according to manufacturers instructions. Sections
were de-waxed in xylene and de-masked with citric acid based antigen
unmasking solution (Vector Labs). Immunohistochemical analysis of
CD68 (1:00 dilution, anti-human mouse clone PG-M1 m0876, DAKO,
Glostrup, Denmark), was conducted after heat-induced epitope
retrieval using a citrate buffer (pH 6; Leica Biosystems) in a decloaking
chamber. Sections were stained using a Leica Vision Biosystems
Bond × immunostaining robot (Leica Biosystems). After blocking in
peroxide for 10min, sections were incubated with the specific primary
anti-human antibodies for 2 hr at room temperature. All incubation
steps were followed by washing in Tris-Buffered Saline and Tween 20
(TBS/T). CD68-stained sections were then incubated for 15min with
prepolymer followed by 15min with polymer conjugated horseradish
peroxidase (HRP) for all antibodies, before3,3-diaminobenzidine (DAB)
visualization andH&E counterstain. Slidesweremounted in Pertex (Cell
Path, Powys, UK). For AnnexinVI staining, endogenous peroxidase, and
non-specific antibody binding were blocked before overnight incuba-
tion at 4 °C with 2 μg IgG/ml anti-Annexin VI antibody (Santa Cruz
Biotechnology). The sections were then washed in PBS, incubated with
diluted biotinylated secondary antibody (1:200) for 30min. After
washing in PBS for 5min, the sections were incubated for 30min with
Vectastain ABC Reagent (Vector Labs). The sections were then
incubated with DAB substrate reagent (0.06% DAB, 0.1% hydrogen
peroxide, in PBS) until the desired stain intensity developed. The
sections were finally dehydrated, counterstained with H&E, and
mounted in DePeX (Sigma). Control sections were incubated with
goat IgG (2 μg IgG/ml) in place of the primary anti-Annexin VI antibody.
2.10 | Analysis of gene expression
RNA was extracted from VICs using RNeasy minikit (Qiagen, West
Sussex, UK), according to the manufacturers instructions. RNA was
reverse transcribed and specific cDNAs were quantified by real-time
PCR using the SYBR green detection method as previously reported
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(Mackenzie et al., 2011; Staines, Zhu, Farquharson, & MacRae, 2014).
Primerswere obtained fromQiagen and PrimerDesign (PrimerDesign,
Southampton, UK).
2.11 | iTRAQ-based quantitative proteomics analysis
VICs were incubated in control and standard CaPi media for 16 hr,
and MVs were isolated by differential centrifugation from the
supernatants to produce two biological replicates for both control
and CaPi media. MVs (25 μg) were separated by one-dimensional
SDSPAGE (412% Bis-Tris Novex mini-gel; Life Technologies),
labeled using an iTRAQ Reagents Multiplex kitfourplex (AB Sciex
UK Ltd, Warrington, UK) and subjected to LC MS/MS analysis (LTQ-
Orbitrap Velos; ThermoFisher Scientific) in two technical replicates
following an established protocol previously described (Broek Vander,
Chalmers, Stevens, & Stevens, 2015).
2.12 | iTRAQ data analysis
The raw mass spectrometric data files obtained were collated into a
single data set using Proteome Discover version 2.0 (ThermoFisher
Scientific) and the Mascot search engine version 2.4 (www.
matrixscience.com). Proteins were selected if they had at least two
unique peptides and a MASCOT peptide score ≥21 (which corre-
sponds to the threshold value for a 95% confidence level). Physical
and functional interaction properties of the identified proteins were
predicted with Ingenuity Pathway Analysis (IPA; Ingenuity System,
Redwood City, CA). Computational prediction of a vector of a signaling
pathway (up or down) was based on mapping of particular positive or
negative regulators associated with the pathway. Data presented
show the differential expression of calcifying MVs relative to the
controlMVs, where q-values represent adjusted p-values derived from
the false discovery rate.
2.13 | Western analysis
Cultured cells were lysed in RIPA buffer (ThermoFisher Scientific).
Immunoblotting was undertaken as previously described (Zhu,
Mackenzie, Millan, Farquharson, & MacRae, 2013). PVDF membranes
(Sigma) were probed overnight at 4 °C with anti-Annexin VI antibody
(1:000, Santa Cruz Biotechnology), anti-PARK7 antibody (1:2000,
Abcam), or anti-RHOA/C (1:2000, Abcam) in 5%BSA. Themembranes
were then washed in TBS/T and incubated with anti-goat IgG-
peroxidase (Dako) for 1 hr (1:3000 in 5%BSA). The immune complexes
were visualized by enhanced chemiluminescence (ECL; GEHealthcare,
Buckinghamshire, UK). Semi-quantitative assessment of band inten-
sity was achieved using ImageJ image analysis software (National
Institutes of Health, Bethesda, MA).
2.14 | Statistical analysis
Two-sample Students t-test was used to analyze the significance
between two sets of data. Formore than two groups, one-way analysis
of variance (ANOVA) using the general linear model (GLM) incorpo-
rating pairwise comparisons was performed. Data are presented as
mean ± standard error of the mean (S.E.M). All statistical analysis was
performed using Minitab 17 (Minitab Inc., Coventry, UK). p < 0.05 was
considered to be significant, and p-values are represented as:
*p < 0.05; **p < 0.01; ***p < 0.001.
3 | RESULTS
3.1 | MVs are present in calcified human aortic valve
tissue
To ascertain whether MVs are central to the etiology of CAVD,
structural studies were initially undertaken to determine the presence
of MVs in clinical tissues. Calcification of aortic valve tissue was
confirmed by Alizarin red and Von Kossa staining (Figure 1ad).
Transmission electron microscopy showed accumulation of vesicular
bodies, ranging from 150 to 250 nm in diameter in the ECM of CAVD
tissue. Many vesicles displayed spindle-like projections of hydroxyap-
atite, as previously reported in MVs derived from chondrocytes
(Figure 1g,h; [Garimella, Sipe, & Anderson, 2004]). Vesicles displaying
this distinctive morphology were not observed in the control tissue,
despite the presence of empty vesicles of comparable sizes
(Figure 1e,f). Assessment of tissue morphology using H&E staining
revealed disorganized ECM in CAVD tissue (Figure 2a,b). Further
staining using CD68 antibodies revealed the presence of inflammation
in CAVD samples (Figure 2c,d).
3.2 | Ca regulates VIC calcification
Initial studies confirmed that rat primary VICs isolated in the present
investigation were free from endothelial contamination. Cells were
negative for the endothelial cell marker, CD31 (Figure 3a). In addition,
cells showed positive staining for both α-SMA (green; Figure 3b) and
vimentin (red; Figure 3c), in agreement with previous reports (Latif
et al., 2015; Liu, Joag, & Gotlieb, 2007).
In ESRD, systemic Ca and Pi concentrations typically exceed
2.4 mM and 2.0 mM, respectively (Reynolds et al., 2004). To
understand the accelerated progression of CAVD in patients with
ESRD, it is essential to appreciate the calcification potential of VICs
exposed to comparable concentrations of these established drivers
of ECM calcification. Ca potently induced VIC calcification at 4.5 mM
(16.4-fold; p < 0.05; Figure 3e) whereas Pi treatment alone had no
effect (Figure 3f). Notably, the treatment of VICs with Ca and Pi
together had a synergistic effect on VIC calcification (2.7mM Ca and
2.5 mM Pi; 10.8-fold; p < 0.001; Figure 3g). The standard CaPi media
induced a significant up-regulation of Ca content in VIC-derived MVs
compared to control media (2.6-fold; p < 0.001; Figure 3h).
A minimum concentration of 2.7mM Ca treatment induced a
significant increase in themRNA expression of the osteogenic markers
Runx2, Msx2, and Alpl (p < 0.01; Figure 4ac). Intriguingly, a counter-
intuitive reduction in the mRNA expression of the MV enriched
phosphatase, Phospho1 (p < 0.001; Figure 4d), with a concomitant
increase in the mineralization inhibitor Enpp1 (p < 0.001; Figure 4e).
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3.3 | Proteomics analysis of MVs from calcified VICs
reveals calcification regulators and exosome markers
To elucidate the specific structural and functional features of MVs
derived from calcified VICs, we analyzed their protein composition
using iTRAQ-based quantitative mass spectrometry analysis (Supple-
mentary Table). Remarkably, a number of established exosomal
proteins were enriched in MVs isolated from VICS cultured with
standard CaPi calcification media, including CD9, CD63, LAMP-1, and
LAMP-2 (Table 1). Of further interest was the concomitant up-
regulation of the calcium-binding Annexins (I, II, III, IV, V, VI, VII, and XI)
(Table 2), which have been previously shown to specifically accumu-
late in chondrocyte and VSMC-derivedmineralization competentMVs
in a calcium-dependent manner (Kapustin et al., 2011; Wang, Xu, &
Kirsch, 2003).
3.4 | Co-localization of Annexin VI with MVs in
human CAVD tissue
Following recent reports establishing that Annexin VI is required
forMVmediated VSMC calcification (Kapustin et al., 2011), we further
investigated the role of this calcium-binding protein in VIC calcifica-
tion. Immunoblotting studies confirmed that treatment with standard
CaPi calcificationmedia induced a significant up-regulation of Annexin
VI expression in rat VIC-derived MVs compared to control media
(Figure 5a,b). IPA revealed novel putative interactions between
Annexin VI and other proteins within the MV, including vimentin
and filamin A (FLNA) (Figure 5c). The enrichment of Annexin VI in
calcifying MVs was further supported by immunohistochemical
assessment of calcified human aortic valves, which revealed higher
expression of Annexin VI (Figure 6c,d), compared to control valve issue
FIGURE 1 MV deposition in the ECM of human calcified aortic valve tissue (a,b). Aortic valve calcification was confirmed by Alizarin red and
Von Kossa staining (c,d). Arrows indicate positive areas of staining. Transmission electron microscopy shows (g,h) MVs with spindle-like
projections resembling hydroxyapatite crystal needles in calcified tissue, and (e,f) empty vesicle structures in control tissue (arrows). Scale
bars = 500 μm (Alizarin red/Von Kossa); 500 nm (TEM)
FIGURE 2 Inflammation in CAVD tissues. (a,b) H&E staining of stenotic aortic valve tissues showing disorganized ECM, and (c,d) CAVD
tissues stained for CD68, a monocyte and macrophage marker showing the presence of inflammation by positive macrophage staining
(arrows). Scale bars = 500 μm (H&E); 200 μm (CD68)
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(Figure 6a,b). Subsequent immunogold labeling confirmed the
co-localization of Annexin VI expression with MVs in CAVD tissue
(Figure 6g,h).
3.5 | Identification of novel putative MV pathways
With a view to highlighting novel biological processes underpinning
MV-mediated calcification in VICs, we used IPA to identify canonical
pathways, biological functions, and networks of interacting proteins.
Key pathways crucial to cardiovascular function were identified,
including aldosterone, P2Y purinergic receptor signaling and thrombin
signaling pathways (Figure 7a), Rho signaling (Figure 7b) and metal
binding (Figure 7c). Of particular interest was the discovery of several
copper-associated proteins within the calcifying MVs (Figure 7c),
including Protein deglycase DJ-1 (PARK7) which functions as a redox-
sensitive chaperone and as a sensor for oxidative stress (Shendelman,
FIGURE 3 Calcium regulates VIC calcification. Immunofluorescence staining of rat primary VICs demonstrates negative staining for (a) the
endothelial cell marker CD31 and positive staining for (b) smooth muscle actin (SMA; green) and (c) vimentin (red). (d) Representative image of
negative control (NC) staining. Calcium deposition in VICs treated with (e) calcium (Ca) alone (2.75.4 mM) (f) phosphate (Pi) alone (25.0mM)
and (g) calcium and phosphate in combination (1.52.7 mM Ca/1.52.5 mM Pi). (h) Calcium content of MVs derived from VICs cultured in
control and standard CaPi medium. Results are presented as mean ± S.E.M. *p < 0.5; **p < 0.01; ***p < 0.001 compared with control; n = 6
FIGURE 4 Calcium regulates osteogenic gene marker expression in VICs. Fold change in the mRNA expression of (a) Msx2 (b) Runx2 (c) Alpl
(d) Phospho1 and (e) Enpp1 in VICs treated with calcium (1.55.4 mM) for 5 days. Results are presented as mean ± S.E.M. **p < 0.01;
***p < 0.001 compared to control; n = 6
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Jonason, Martinat, Leete, & Abeliovich, 2004; Zhou, Zhu, Wilson,
Petsko, & Fink, 2006). Further studies conducted using western blot
analysis on RVIC Sv40T-derivedMVs confirmed the higher expression
of Rho A/C and Park7 in calcifying MVs (Figure 7d).
4 | DISCUSSION
Given the significant contribution of increased circulating Ca to the
arterial medial calcification associated with ESRD, in conjunction with
reports showing the concentration of Ca in calcified aortic valves to
exceed 13.5mM/g tissue (Dahm et al., 2000), a more complete
understanding of the role of calcium in aortic valve calcification is
essential.
We report for the first time that VIC calcification in vitro can be
driven by elevated Ca levels, with a concomitant increase in the
expression of osteogenic markersMsx2, Runx2, and Alpl. Pi treatment
alone was surprisingly ineffective at calcification induction. Intrigu-
ingly, a notable synergistic effect of Ca and Pi in combination on VIC
calcification was observed, corroborating earlier reports demonstrat-
ing that elevated Ca induced human VSMC calcification in vitro with a
synergistic effect of Ca and Pi (Reynolds et al., 2004). Abnormalities in
Ca and Pi metabolism may therefore, directly underpin the increased
susceptibility of ESRD patients to accelerated progression of CAVD.
This study offers new insight into the role ofMVs in cardiovascular
disease and provides direct evidence to suggest that MVs contribute
to the pathological process of aortic valve calcification. Our experi-
ments have established that MVs are released by viable VICs,
particularly in the presence of elevated levels of extracellular Ca
and Pi. These data support recent mechanistic studies of VSMC-
derived MVs (Kapustin et al., 2011), which proposed that Ca-loaded
vesicles are released from cells to protect against the cytotoxic effects
of intracellular Ca overload (Fleckenstein-Grün, Thimm, Czirfuzs,
Matyas, & Frey, 1994; Hsu & Camacho, 1999). Furthermore, our
ultrastructural analyses have identified the presence of MVs in
calcified human aortic valves. These data extend previous reports
demonstrating the existence of MVs in medial arterial calcification
(Kim, 1976), and atherosclerotic intimal plaques (New et al., 2013).
Recent data have challenged current views on the plasma
membrane origin ofMVs, identifying VSMC-derivedMVs as exosomes
emanating from intracellular MV bodies (Kapustin et al., 2015). In the
present study, iTRAQ-based quantitative mass spectrometry analysis
revealed that a number of established exosomal proteins were
enriched in MVs isolated from calcified VICs. It is therefore,
conceivable that unlike bone-derived MVs, which are understood
to be released through polarized budding (Cui et al., 2016), MVs
implicated in cardiovascular calcification are of exosomal origin.
Further studies are therefore, required to more fully characterize the
regulation of MV biogenesis in aortic valve calcification.
MVs produced by calcifying chondrocytes and VSMCs have been
shown to contain Annexin II, V, and VI, the membrane-associated
proteins known to mediate Ca influx into MVs (Balcerzak et al., 2008;
Kapustin et al., 2011; Xiao et al., 2007). Here we demonstrate the
up-regulation of Annexins I, II, III, IV, V, VI, VII, and XI in calcifying
VIC-derived MVs, underscoring the significance of the Annexin family
in the process of cardiovascular calcification. We reveal for the first
time not only the presence of Annexin VI expression in calcified human
aortic valve tissue, but also the co-localization of Annexin VI
expression within calcifying MVs. These data suggest a novel role
for Annexin VI in the regulation of calcium homeostasis and MV
release in CAVD, building on previous reports demonstrating a
specificity of Annexin V for macrophage-derived MVs (New et al.,
TABLE 1 Up-regulation of exosomal proteins in calcified VIC-derived MVs
Protein Name
Gene
name UniProt ID
Mean
ratio
Q-
value
CD 9 antigen CD9 B1WBM0 8.99 0
CD 63 antigen CD63 F1LPA7 3.78 0.0035
Lysosomal associated membrane protein 1 LAMP-1 P14562 49.60 0
Lysosomal associated membrane protein 2 LAMP-2 F1LLX8 41.81 0
Tumor susceptibility gene 101 Tsg101 F1LRB7 11.45 0
Heat shock 70 kDa protein 8 Hspa8 P63018 12.50 0
Annexin V Anxa5 Q66HH8 31.17 0
Heat shock protein 90, class A member 1 Hsp90aa1 P82995 13.81 0
Enolase 1 Eno1 Q5BJ93 20.17 0
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta
polypeptide
Ywhaz A0A0G2JV65 6.35 0
TABLE 2 Up-regulation of Annexins in calcified VIC-derived MVs
Protein Gene name UniProt ID Mean ratio Q-value
Annexin I Anxa1 P07150 52.28 0
Annexin II Anxa2 Q07936 43.54 0
Annexin VII Anxa7 Q6IRJ7 34.46 0
Annexin VI Anxa6 Q6IMZ3 31.39 0
Annexin V Anxa5 Q66HH8 31.17 0
Annexin XI Anxa11 Q5XI77 24.67 0
Annexin IV Anxa4 Q5U362 20.31 0
Annexin III Anxa3 F1M0L7 9.69 0.018
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2013) and Annexin VI for VSMC-derived MVs (Chen et al., 2008;
Kapustin et al., 2011) in aortic calcification. Indeed, the cell type-
dependent enrichment of annexins in calcifying MVs may be a key
factor in the regulation of MV release and calcification potential
within the cardiovascular system.
Despite recent advances in our knowledge, the full mechanisms
underpinning CAVD have yet to be fully elucidated. This study has
clearly demonstrated differential expression of novel proteins
and pathways in calcifying VIC-derived MVs, many of which were
not reported in previous proteomic analyses of calcifying MVs
(Balcerzak et al., 2008; Kapustin et al., 2011; Xiao et al., 2007).
Numerous proteins associated with aldosterone and thrombin
canonical pathways were identified in our analysis, which have
both been previously linked to accelerated vascular calcification
(Borissoff et al., 2012; de Rita, Hackam, & Spence, 2012;
Hillaert et al., 2013). P2Y purinergic receptor signaling was also
up-regulated, which has been recently linked to aortic medial
calcification in chronic kidney disease (CKD) patients through the
activation by uridine adenosine tetraphosphate (Up4A) (Schuchardt
et al., 2012). Additionally, we observed increased expression of
several members of the Rho signaling pathway, which has been
previously shown to be associated with VIC calcification in vitro (Gu
& Masters, 2011). We also identified novel pathways associated
with PARK7, which is involved in copper-dependent signaling and
functions as a redox-sensitive chaperone and as a sensor for
oxidative stress (Shendelman et al., 2004; Zhou et al., 2006).
Furthermore, PARK7 is involved in activating androgen receptor-
dependent transcription (Kolisek et al., 2015), and may therefore,
FIGURE 5 Enriched Annexin VI expression in calcifying VIC-derived MVs and calcified aortic valve tissue. (a) Representative image of
western blotting for Annexin VI in MVs isolated from VICs cultured in control and standard CaPi medium and (b) densitometry quantification
showed increased expression of Annexin VI in calcifying VIC-derived MVs. Results are presented as mean ± S.E.M. *p < 0.05 compared to
control; n = 3. (c) Ingenuity pathway analysis showing the associations between Annexin VI and other proteins within the MV. The functions
mapped by the dataset are represented by pink shadowed blocks. Functional interconnections between the proteins are shown by pink
arrows and blue lines. The blue lines represent direct associations with Annexin VI. Dashed lines represent predicted associations
FIGURE 6 Co-localization of Annexin VI with MVs in human CAVD tissue. Increased Annexin VI expression was observed in (c,d; arrows)
calcified aortic valve compared to (a,b) control tissue. (e,f) Representative images of negative control staining. (g,h) Immunogold labeling
showed co-localization of Annexin VI with MVs (arrows) in calcified aortic valve tissue. Scale bar = 50 μm (Immunohistochemistry); 100 nm
(TEM)
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play a key role in the acceleration of vascular calcification by
testosterone as recently reported by our laboratory (Zhu et al.,
2016).
Together these findings yield novel insights into the mechanisms
of aortic valve calcification and highlight a critical role for VIC-derived
MVs in CAVD. Furthermore, we identify calcium as a key driver of
aortic valve calcification, which may have important implications
for ESRD patients. This data may provide a stepping stone toward
understanding the mechanisms of early calcification in renal failure
patients as well as the establishment of new targets for the
development of future therapeutic strategies for CAVD.
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